WHO Consolidated Guidelines on Tuberculosis, Module 4: Drug-Resistant Tuberculosis Treatment
Professor Amrita Daftary, Member of Faculty at the Dahdaleh Institute, contributed to the World Health Organization's Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment.
In 2019, new evidence pointed to the safety and efficacy of new all-oral, shorter treatment regimens for drug resistant tuberculosis (DRTB), tuberculosis (TB) that is resistant to the most common anti-TB drugs available. It had been over 50 years since the last new TB drug was developed. The guidelines are the result of a commissioned review of all evidence around the shorter, all-oral regimens.
Calibrating to scale: a framework for humanitarian health organizations to anticipate, prevent, prepare for and manage climate-related health risks »
« Think 7 USA 2020: Report of the Think 7 Summit